News

10.06.2021

On-demand viewing is available

The 2021 Annual Meeting sessions and eTalks have been available for on-demand viewing on the virtual event platform since May 31. To access the platform, conference participants use the same login data used to access the conference.

more
  • The lectures and eTalks are available on-demand in the respective virtual rooms through the end of June.
  • The virtual industry exhibition is also still accessible.
  • If a speaker did not consent to the on-demand format, the presentation is not included.

If you have any further questions or requirements, please feel free to contact us. You may reach us by phone: +49 (0) 611 204809-240 or via email: cimt@wikonect.de.

19.05.2021

ACIR meeting summary

Selected talks from the virtual 18th CIMT Annual Meeting, including the keynote lecture by Ugur Sahin, were covered by ACIR. The meeting summary can be accessed on the ACIR web page.

 

more

CIMT thanks the ACIR team for their coverage of this year's virtual Annual Meeting.

Accelerating Cancer Immunotherapy Research (ACIR) publishes weekly, free-of-charge and readily accessible synopses of the key advances in the fast moving and multifaceted field of cancer immunotherapy. For more information see https://acir.org

Read the report of the 18th CIMT Annual Meeting at https://acir.org/weekly-digests/2021/may/cimt-annual-meeting-2021#keynote

 

18.05.2021

On-demand session viewing

The Annual Meeting virtual platform is currently under construction. Thank you for your patience while we are preparing the session talks for on-demand viewing. The platform will re-open at the end of May.

more

All registered participants of the CIMT Annual Meeting will have continued access to the virtual meeting platform where eTalks and session talks can be viewed on-demand through the end of June.

14.05.2021

2021 eTalk Award Winners

Six early-career researchers have been chosen by the CIMT poster jury to receive the 2019 CIMT Poster Awards. One eTalk winner was selected by the meeting audience.:
We congratulate Alejandro Hernandez-Sanchez (German Cancer Research Center), Paola Bonaventura (Cancer Research Center of Lyon), Leonie Rosenberger (Charité-Universitätsmedizin ), Miro Raeber (University Hospital Zurich), Marie Christine Viuff (Technical University of Denmark), Francesca Simoncello  (International Centre for Genetic Engineering and Biotechnology)

more

Cellular Therapy
Leonie Rosenberger
Charité-Universitätsmedizin
Abstract 137
Mutation-specific T cell receptors from tumor-bearing hosts display optimal functionality

Therapeutic Vaccination
Alejandro Hernandez-Sanchez  
German Cancer Research Center-DKFZ
Abstract 32
Immunogenicity and HLA binding affinity of MSI-associated frameshift peptide neoantigens

New Targets and New Leads
Paola Bonaventura
Cancer Research Center of Lyon
Abstract 66
Identification of shared tumor epitopes from endogenous retroviruses inducing high avidity cytotoxic T cells for cancer immunotherapy

Immunomonitoring
Marie Christine Viuff
Technical University of Denmark
Abstract 164
Mapping of HPV-specific CD8+ T cells and immune signatures in cervical intraepithelial neoplasia and cancer

Tumor Biology & Interaction with the Immune System
Francesca Simoncello  
International Centre for Genetic Engineering and Biotechnology
Abstract 196
CXCL5-mediated accumulation of SiglecFhigh neutrophils in lung tumor tissues impairs CD8 T cell responses and limits the efficacy of PD-L1 checkpoint blockade

Improving Immunity
Miro Raeber
University Hospital Zurich
Abstract 75
Interleukin-2 signals converge in a lymphoid–dendritic cell pathway that promotes anticancer immunity

Audience Choice
Valentina Volpin
Regensburg Center for Interventional Immunology (RCI)
Abstract 56
The serine/threonine kinase CAMK1D confers immune resistance of PD-L1 refractory tumor cells against tumor-reactive cytotoxic T cells

We would like to thank Immatics Biotechnologies for their generous support of the 2021 eTalk Awards.

10.05.2021

CIMT 2021 opens in Mainz, Germany

The virtual 18th Annual Meeting of the Association for Cancer Immunotherapy CIMT was opened  today by CIMT President Özlem Türeci  with over 800 cademic and clinical professionals in the fields of tumor immunology attending online. Over 220 submitted abstracts are presented online as eTalks.

more

The 2021 meeting offers eight plenary plenary sessions offers sessions on topics such as cellular therapy, neontigens/vaccines, immunoguiding, tumor microenvironment, microbiota, bioinformatics, improving immunity, and regulatory research, plus a special COVID-19−Immuno-Oncology Cross Talk session.

 

03.05.2021

2021 abstracts are online

All abstracts and the day-to-day 2021 Annual Meeting program are online can be accessed at www.meeting.cimt.eu/program.

 

more

During the meeting, the abstracts and day-to-day program can be viewed on the virtual meetig platform.

28.04.2021

2021 CIMT Lifetime Achievement Award

The Italian immunologist Alberto Mantovani will be honored by CIMT for life-time achievements in cancer immunotherapy research. The prize will be awarded on the evening of Monday, May 10 at 7 p.m., as part of the virtual Annual Meeting of the Association for Cancer Immunotherapy CIMT, May 10-12, 2021.

more

On May 10, 2021, the Italian immunologist Alberto Mantovani will be honored for life-time achievements in cancer immunotherapy research. The prize, which is awarded every other year by the Association for Cancer Immunotherapy CIMT, honors European scientists who have made significant contributions to cancer immunotherapy research over their careers. Alberto Mantovani is Emeritus Professor of Pathology at the Humanitas University in Milan, and Scientific Director of the Istituto Clinico Humanitas.

Over his 50-year career, Alberto Mantovani, an expert on the molecular mechanisms of innate immunity and inflammation, has significantly advanced knowledge in the field of immunology by formulating new paradigms and identifying new molecules and functions. In addition, he has furthered awareness of science and medicine by authoring books and articles on immunology, vaccines and health targeted at the general public.

Downloads:
CIMT Lifetime Achievement Award 2021-Alberto Mantovani.pdf

16.04.2021

Abstract authors have been notified

All abstract authors have been notified and have been sent information about setting up their presentations. The CIMT eTalk sessions will feature a total of 221 scientific eTalks.

more

All eTalks will be available for on-demand viewing via the conference platform from May 10 through June 12, 2021. All accepted abstract texts will be included in the online program book and will be published online on May 3.

During their eTalk Session, all abstract presenters can engage with conference participants in personal Q&A chat rooms.

All eTalk presenters have the chance to be selected for best eTalk in their category. The eTalk awards will be presented at the closing of the conference (May 12, 6:30-7:00 pm).
The 2021 eTalk awards are supported by Immatics.

12.03.2021

Abstract submission extended to March 24

For late breaking abstracts, the 2021 abstract submission and advance registration has been extended to March 24 (midnight CET).

more

Submit your abstract in the following categories: · Therapeutic Vaccination · Immunomonitoring · Cellular Therapy · New Targets & New Leads · Tumor Biology and Interaction with the Immune System · Improving Immunity

25.02.2021

Apply for a registration waiver

CIMT will select young scientists from underrepresented countries for free conference admission. Free conference admission can only be extended to scientists who have submitted an abstract and are registered to attend the meeting.

more

In previous years, travel award winners came from Argentina, Turkey, Hungary, Greece, Portugal, Czech Republic, Cuba, Chile, Poland, India, Egypt, among others.

Go to www.meeting.cimt.eu/travel-awards for more information.

29.01.2021

2021 registration and abstract submission is open

For its virtual congress, the CIMT program committee is calling for abstract submission in six  categories: Therapeutic Vaccination, Cellular Therapy, New Targets and New Leads, Immunomonitoring, Tumor Biology and Interaction with the Immune System, Improving Immunity.
The abstract submission deadline is set for March 14, 2021.

more

All abstract authors/presenters must register for the conference prior to submitting an abstract.

23.11.2020

2021 CIMT Annual Meeting

Save the date for the 2021 CIMT Annual Meeting which will take place in a virtual format, from May 10-12, 2021. CIMT will take the opportunity to provide international participants with high-level scientific learning and knowledge exchange regardless of their location or travel restrictions. We will post more information as soon as it becomes available.

more

To receive timely notification on the 2021 call for abstracts and other conference information, please consider signing up for our newsletter.

20.03.2020

The 2020 CIMT Annual Meeting will not take place

The CIMT Executive Board has decided to not hold the CIMT Annual Meeting, which was scheduled for May 5-7, 2020, in Mainz, Germany. This decision was made after considering current information, guidance and forecasts issued by the German federal and regional governments concerning the novel coronavirus pandemic. We also took into consideration the worldwide travel and gathering restrictions which have been put in place and the yet unforeseeable duration of these measures.

more

Ensuring the health and safety of our participants, staff and the greater community is our first priority.

No alternative date has been scheduled at this point in time, but we will look into opportunities to hold the meeting later this year.
 
For now, CIMT will refund all registration and exhibitor fees in full.
Refunds will take several weeks. We would like to thank you in advance for your patience.
 
If you have any questions, please contact CIMT by email at office@cimt.eu.

28.02.2020

Abstract submission extended to March 6

For late breaking abstracts, the 2020 abstract submission has been extended to March 6.

more

For late breaking abstracts, the 2020 abstract submission has been extended to March 6.

28.02.2020

Statement regarding novel coronavirus

At this time, there are no plans to cancel the 2020 Annual Meeting. We will provide further updates as events warrant.

more

CIMT is closely monitoring the continuing developments pertaining to the novel coronavirus. We want to assure colleagues planning to attend the 2020 Annual Meeting that safety and security are our top priorities.

At this time, there are no plans to cancel the Meeting. CIMT is tracking all travel restrictions issued by the German Government, as well as information and guidance from the Robert-Koch-Institute www.rki.de, the German Federal Ministry of Health www.bundesgesundheitsministerium.de, and the World Health Organization www.who.org.

We will provide further updates as events warrant. Colleagues who have questions can contact CIMT by email at congress@cimt.eu or by phone at +49-6131-5547400.

17.01.2020

Alan Korman to deliver keynote address at CIMT 2020

Alan Korman of Vir Biotechnology, Inc. will present the keynote lecture at the 18th CIMT Annual Meeting. A pioneer in the development of cancer immunotherapies, Dr. Korman will give an overview of the history and future of CTLA-4 therapies.

more

Dr. Korman's renowned work at BMS and Medarex led to the development of two of the first approved cancer immunotherapy drugs, ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) and their combination, constituting a major breakthrough in cancer treatment for patients worldwide.

08.01.2020

2020 Registration and abstract submission is open

The CIMT program committee is calling for abstract submission in six  categories: Therapeutic Vaccination, Cellular Therapy, New Targets and New Leads, Immunomonitoring, Tumor Biology and Interaction with the Immune System, Improving Immunity.

more

The abstract submission deadline is set for February 28, 2020.

12.11.2019

2019 CIMT meeting report published

The report of the 17th Annual Meeting of the Association for Cancer Immunotherapy CIMT has been published in the November 11 edition of Human Vaccines & Immunotherapeutics.

more

The open access meeting report summarizes the highlights of the 2019 CIMT Annual Meeting which took place in Mainz, Germany, May 21-23.

CIMT 2019: report on the 17th Annual Meeting of the Association for Cancer Immunotherapy
Jan David Beck, Matthias Birtel, Erik Haefner, Isabell Sofia Keil, Daniel Reidenbach, Nadja Salomon, Ikra Gizem Yildiz & Mustafa Diken

04.06.2019

Save the Date

The 18th CIMT Annual Meeting will take place May 5-7, 2020 in Mainz, Germany.

more

Sign up for our newsletter to stay informed and to receive announcements about CIMT meetings, seminars and events.

23.05.2019

Congratulations 2019 Poster Award Winners

Six early-career researchers have been chosen by the CIMT poster jury to receive the 2019 CIMT Poster Awards:
Anna Mueller-Schoell (Freie Universität Berlin), Thomas Roesler (TRON – Translationale Oncology Mainz), Hannah Wurzer (Luxembourg Institute of Health), Juliane Schuhmacher (University of Tübingen), Ehsan Ghorani (University College London), Su Yin (Esther) Lim (Macquarie University)

more

 

Cellular Therapy
Anna Mueller-Schoell
Freie Universität Berlin
Abstract 100
CAR-T cell therapy: Investigating clinical challenges using a modelling & simulation framework


Therapeutic Vaccination
Thomas Roesler
TRON – Translationale Oncology Mainz
Abstract 37
Modelling immunogenicity with omics data integration


New Targets and New Leads
Hannah Wurzer
Luxembourg Institute of Health
Abstract 231
The great escape: role of the actin cytoskeleton in cancer immune evasion


Immunological Monitoring
Juliane Schuhmacher
University of Tübingen
Abstract 70
RhoC vaccination induces a robust and long-lasting immune response in a clinical phase I/II prostate cancer trial


Tumor Biology & Interaction with the Immune System
Ehsan Ghorani
University College London
Abstract 144
Imbalance between early and late differentiated intra-tumour CD4 T cells is associated with mutational burden and regulatory T cell abundance in non-small cell lung cancer


Improving Immunity
Su Yin (Esther) Lim
Macquarie University
Abstract 238
Dynamic changes in transcriptome and cytokine expression in melanoma patients treated with combination PD-1 and CTLA-4 inhibitors

Downloads:
1032_CIMT2019_klein.jpg

22.05.2019

Wolf Fridman receives CIMT Lifetime Achievement Award

On May 21, the French immunologist Wolf Herman Fridman was honored for life-time achievements in cancer immunotherapy research.  The prize, which is awarded by the Association for Cancer Immunotherapy CIMT, honors European scientists who have made significant contributions to cancer immunotherapy research over their careers.

more

Wolf Fridman is professor emeritus at Paris Descartes University as well as the founder of Cordeliers Research Centre, and president of the Canceropole Ile de France.
The award committee emphasizes Fridman’s outstanding contribution to a deeper understanding of cancer immunology and the tumor environment.
 “Wolf Fridman is an extraordinary scientist and a leader in the European cancer immunotherapy movement” says Christoph Huber, President of CIMT, about the award committee’s decision.  “With his broad research interests over a long career, Wolf has influenced so many facets of this field, from basic cancer immunology to the various ways in which this impacts clinical prognosis. His work and mentorship have given rise to a new generation of scientific leaders in European cancer immunology“.
The prize, which is endowed with 10,000 EUR, was awarded on the evening of Tuesday, May 21 at the Rheingodlhalle Congress Center in Mainz, Germany, as part of the Seventeenth Annual Meeting of the Association for Cancer Immunotherapy CIMT.

 

2019 CIMT Lifetime Achievement Award

21.05.2019

Congratulations to the new CIMT President

Özlem Türeci has been elected President by the members of the Association for Cancer Immunotherapy CIMT.

Dr. Türeci succeeds Christoph Huber who led the organization for 17 years.

more

Dr. Türeci has been a CIMT board member for the past three years.

Özlem Türeci is an M.D. with over 25 years of experience in cancer research and immuno-oncology, specifically in the identification of immunotherapeutic drug targets and the development of antibodies, as well as vaccine-based therapies. Dr. Türeci co-founded GanymedPharmaceuticals as Chief Scientific Officer and was its Chief Executive Officer from 2008-2017, developing a new generation of first-in-class antibodies in solid cancers. Dr. Türeci is now a management board member of BioNTech. She is also a chair and co-initiator of Ci3, the German Cluster Initiative of Individualized ImmunIntervention(Ci3) e.V., based in Mainz, Germany. She has authored over 110 peer-reviewed publications and is an inventor on more than 80 patents and patent applications.

 

CIMT

The Association for Cancer Immunotherapy

Welcome to Europe’s largest meeting focused on cancer immunotherapy research and development.

CIMT is a members-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer immunotherapies. CIMT was founded in 2002 by physicians and researchers from different fields of clinical and theoretical medicine as an independent non-profit organization. CIMT has its offices in Mainz, Germany, and is financed by donations, congress fees, industry sponsorship and by public and foundation grants.

Visit the CIMT website | www.cimt.eu